Defined as "total care" by the World Health Organization[@b1], the primary aims of palliative cancer care are to promote adequate symptom control and to optimize quality of life before a "timely, dignified and peaceful death" in people with cancer[@b2]. Early, appropriate palliative cancer care can reach the goal of improving quality of life, increasing survival time, and reducing the need of aggressive care during the end of life[@b3]. Current model has shifted from confining palliative cancer care to the last 6 months of life to the whole disease trajectory[@b4]. Growing number of aging populations with increasing prevalence of cancer have made palliative care a global health priority[@b5][@b6]. While the role of palliative care is widely recognized, effective palliative care interventions are sparse[@b7][@b8].

In view of limitations in conventional palliative care, the potential role of traditional Chinese medicine can be explored. It has long been used as a supportive intervention for cancer patients in China and other Asian countries[@b9]. It is also becoming popular in western countries in palliative cancer care[@b10]. As one of the major treatment modalities in traditional Chinese medicine, Chinese herbal medicine (CHM) has been widely used as adjuvant cancer treatment among Chinese communities[@b9][@b11]. Numerous systematic reviews (SRs) have been conducted to synthesize the effectiveness of CHM in palliative cancer care. One of the SRs published in English has synthesized evidence on the effectiveness of CHM on cancer symptom management. The results indicated mixed results for improving nutritional status, pain and quality of life but it is likely to be outdated[@b12]. There are also some reports on CHM's effectiveness in reducing side effect of chemotherapy and in improving survival[@b13].

We conducted an overview of meta-analysis to critically appraise and summarize clinical evidence on CHM for cancer palliative care. We aim to provide a broad overview on available evidence, which will inform clinicians, cancer patients and policy makers, and to identify methodological limitations of existing SRs so as to guide future research in this area.

Results
=======

Characteristics of included SRs
-------------------------------

A total of 844 citations were retrieved from the databases, among which 51 SRs met the inclusion criteria and were included in this overview ([Fig. 1](#f1){ref-type="fig"}). The 51 included SRs were published between 2004 and 2014, with 34 (66.7%) published after 2012. Characteristics of these SRs can be found in [Table 1](#t1){ref-type="table"}. Eleven SRs (21.6%) were published in English and the remaining 40 (80.4%) were published in Chinese. Thirty-six SRs (70.6%) searched both international and Chinese databases and 30 of them (83.3%) reported the publication languages of included studies, with 24 (80.0%) only identified Chinese publications. Two (3.9%) were Cochrane SRs. Thirty-seven (72.5%) SRs only included randomized controlled trials (RCTs) while the remaining 14 (27.5%) included both RCTs and non-RCTs. Among 48 SRs that provided a cutoff date on literature search, 29 (60.4%) conducted literature search after 2011 with the most recent search conducted in January 2013. Lists of the included SRs were shown in [Appendix 3](#S1){ref-type="supplementary-material"}.

Twenty (39.2%) SRs only included lung cancer patients, among which 19 SRs specifically focused on non-small cell lung cancer (NSCLC) patients. The remaining 31 SRs summarized evidence on patients with gastric (8 SRs), colorectal (6 SRs), liver (6 SRs), breast (2 SRs), cervical (1 SR), esophageal (1 SR), and nasopharyngeal (1 SR) cancers. Six SRs summarized evidence on various types of cancer.

All CHM interventions were used as an adjuvant therapy in the included SRs, with comparisons being CHM plus chemotherapy and/or radiotherapy versus chemotherapy and/or radiotherapy alone. Details on CHM evaluated can be found in [Table 1](#t1){ref-type="table"}. Twenty-eight SRs reviewed a single, specific type of CHM treatment, while the remaining 23 SRs summarized evidence on various types of CHM. Details of CHM reviewed in the 23 SRs were shown in [Appendix 4](#S1){ref-type="supplementary-material"}.

Three types of outcomes were summarized among identified SRs, with 29 SRs provided results on quality of life (QoL), 23 SRs on survival rate and 11 SRs on chemotherapy and/or radiotherapy induced toxicity. These toxicities included leucopenia (9 SRs), nausea and vomiting (8 SRs), thrombocytopenia (6 SRs); anemia (5 SRs), neurotoxicity (2 SRs), diarrhea (1 SR), and stomatitis (1 SR). Details can be found in [Table 1](#t1){ref-type="table"}.

Methodological quality of included SRs
--------------------------------------

Methodological quality of included SRs was shown in [Table 2](#t2){ref-type="table"}. Forty-nine (96.1%) SRs performed a comprehensive literature search. Forty-four (86.3%) SRs assessed and documented risk of bias among included studies. Thirty-nine (76.5%) SRs used appropriate methods to combine the findings. Nineteen (37.3%) SRs did not search for grey literature. Sixteen (31.4%) SRs provided the characteristics of included studies. Only two SRs (3.9%) provided a protocol. Although 39 (76.5%) SRs listed all included studies, only two (3.9%) provided a list of both included and excluded studies. No SRs stated conflict of interest for both the SR and the included studies. Nine (17.6%) stated conflict of interest for the SR itself, eight of which were published in English and only one was published in Chinese.

Effectiveness of CHM for cancer palliative care
-----------------------------------------------

All included SRs used similar criteria for measuring the outcomes. QoL was assessed with the Karnofsky Performance Status (KPS) scale. A KPS score increment \>10 score was defined as clinical improvement, while patients with KPS score increment \>0 were considered as respondents. Survival was measured with survival rate across the follow up duration. Chemotherapy toxicities were measured by the World Health Organization toxicity criteria. Details on the effectiveness as well as quality of evidence of CHM for improving QoL and survival rate; and in reducing chemotherapy and/or radiotherapy related toxicities are shown in [Tables 3](#t3){ref-type="table"}--[](#t4){ref-type="table"}[5](#t5){ref-type="table"}. In the paragraphs below, abbreviation of the CHM is used if the SR focused specifically on one particular type of CHM. The general term of "CHM" is used if the SR provided evidence on various type of CHM.[](#t4){ref-type="table"}

QoL
---

### NSCLC

Fourteen SRs summarized evidence on CHM as an adjuvant intervention for improving QoL in NSCLC patients. These 14 SRs reviewed the effects of Compounds Kushen injection (KS) (3 SRs), Kanglaite injection (2 SRs), Shenqi Fuzheng injection (SFI) (2 SRs), Kang Ai injection (2 SRs), Zijinglong (1 SR), Xiaoaiping (1 SR), Shenfu injection (1 SR). Two reviewed mixed types of CHM. When compared to chemotherapy alone, combination of CHM and chemotherapy significantly improved QoL, as shown in the meta-analyses results. All but two meta-analyses showed homogeneity, with I^2^ values of 57.0% and 77.0% respectively.

### Liver cancer

Three SRs summarized the add-on effects of CHM on QoL in liver cancer patients. One SR focused on KS and the other two reviewed a range of CHM. Meta-analyses from these three SRs showed that patients treated with KS or CHM plus transcatheter chemoembolization (TACE) had significantly greater improvement on QoL than those who received TACE alone. One SR also showed that CHM plus TACE provided a significantly higher increment on KPS score (pooled MD = 10.03, 95% CI = 8.98--11.07) than TACE alone. Nevertheless, high level of heterogeneity (I^2^ = 95%, p \< 0.001) exist in this meta-analysis.

### Gastric cancer

Two SRs reviewed the evidence of SFI plus chemotherapy for improving QoL among gastric cancer patients. Meta-analyses showed promising effect of SFI in both SRs. One which included TNM stage I-IV patients showed a significantly improved response (improvement rate, pooled RR = 3.14, 95% CI = 2.11--4.69). The other one which only included TNM stage III--IV patients demonstrated a significant, yet lesser effect (responder rate, pooled OR = 1.48, 95% CI = 1.26--1.57). Another SR which included various type of CHM found that, when compared to conventional care alone, combination of CHM and conventional care can slightly improve QoL score (pooled MD = 0.51, 95% CI = 0.21--1.82) in TNM stage III--IV patients. High heterogeneity (I^2^ = 86%, p \< 0.01) was observed for this meta-analyses.

### Colorectal cancer

Two SRs have reported add-on benefit of CHM in improving QoL. One Cochrane SR summarized evidence on advanced colorectal cancer patients, who are diagnosed as reaching stage IV in the American Joint Committee on Cancer Staging System or stage D with Union Internationale Contrele Cancer. The other SR did not provide tumor stage of included patients.

### Breast cancer

Two SRs reported that, when compared to chemotherapy alone, KS plus chemotherapy significantly improved QoL in breast cancer patients.

### Nasopharyngeal cancer

One SR summarized evidence of various CHM for improving QoL in patients with nasopharyngeal cancer. Meta-analysis showed that, the combination of CHM and radiotherapy led to a slight improvement in patients' QoL (pooled RR = 1.60, 95% CI = 1.30--1.96) when compared to radiotherapy alone.

### Various types of cancer

Four SRs reviewed the add-on effect of CHM on QoL among patients with different diagnoses. All SRs reported the add-on benefit of CHM on top of chemotherapy or radiotherapy in improving QoL, when compared to chemotherapy or radiotherapy alone. These SRs studied astragalus injection, Reishi mushroom extract, Xiaoaiping injection and SFI respectively.

### Quality of evidence

Majority (93.5%) of the evidence reviewed is of moderate quality. Evidence on gastric cancer is of low quality, and in another SR on various types of cancer the evidence is of high quality.

Survival rate
-------------

### NSCLC

Four SRs reviewed various types of CHM plus chemotherapy versus chemotherapy alone for improving survival rate among NSCLC patients. All SRs showed that additional CHM treatment can slightly improve 1-year survival rate, although one SR reported that the benefit were not of significance. Other pooled results also showed that, CHM plus chemotherapy can significantly improve 2-year (pooled OR = 2.26, 95% CI = 1.16--3.99), 3-year (pooled OR = 2.59, 95% CI =  1.51--4.45) and 5-year (pooled OR = 2.45, 95% CI = 1.24--4.84) survival rates when compared to chemotherapy alone.

### Lung cancer

One SR summarized evidence of various types of CHM plus chemotherapy or/and radiotherapy versus chemotherapy or/and radiotherapy alone for improving survival rate in lung cancer patients. Meta-analysis showed that CHM provide an add-on benefit in improving 2-year survival rate (pooled OR = 3.44, 95% CI = 2.04--5.80).

### Liver cancer

Five SRs reviewed evidence of CHM plus TACE versus TACE alone for improving survival rate. CHM interventions included KS and mixed types of CHM. Meta-analyses showed that CHM provided additional benefits in improving 0.5-year, 1-year, 1.5-year, 2-year and 3-year survival rates. It should be noted that significant heterogeneities were found in three meta-analyses: 1.5-year survival rate (I^2^ = 70%, p = 0.009) in Wu 2009 b, 1.5-year survival rate (I^2^ = 63%, p = 0.03) and 3-year survival rate (I^2^ = 67%, p \< 0.001) in Cheung 2013.

### Gastric cancer

One SR reported that Kanglaite injection plus chemotherapy provide significant improvement on 1-year survival rate of gastric cancer patients (pooled OR = 6.74, 95 CI%  = 2.74--16.62) when compared to chemotherapy alone. Another SR found no significant benefit on 1-year survival rate (pooled RR = 1.25, 95% CI = 0.73--2.14) among TNM stage III--IV gastric patients using Huangchansu. Three other SRs included various types of CHM and meta-analyses showed that CHM plus chemotherapy can significantly improve 1-year, 2-year, 3-year and 5-year survival rates in gastric cancer patients.

### Colorectal cancer

Four SRs summarized evidence on the add-on effect of CHM for improving survival rate. Meta-analyses showed that CHM plus chemotherapy provide significant greater improvement on the 0.5-year, 1-year, 2-year, 3-year, 4-year and 5-year survival rates, as compared to chemotherapy alone.

### Nasopharyngeal cancer

Meta-analysis from a SR showed that, when compared to radiotherapy alone, combination of CHM and radiotherapy can slightly improve 3-year survival rate (pooled RR = 1.30, 95% CI = 1.03--1.63).

### Esophageal cancer

One SR summarized evidence on KS. Although the addition of KS slightly improved 3-year survival rate (pooled OR = 1.86, 95% CI = 0.96--3.62) when used on top of chemotherapy, no significant difference was found when compared to chemotherapy alone.

### Cervical cancer

A SR reported that, when compared to radiotherapy or chemotherapy alone, additional CHM treatment improved patients' 1-year survival rate significantly (pooled OR = 4.16, 95% CI = 1.97--8.78).

### Various types of cancer

One SR reviewed evidence on the add-on effect of KS among patients with various types of cancer. The results showed that KS only provide a small add-on improvement for 1-year and 2-year survival rates.

### Quality of evidence

Only 28.9% of the evidence on prolonging survival time showed high quality, while 60.0% is of moderate quality and the remaining 11.1% is of low quality.

Toxicities related to Chemotherapy or Radiotherapy
--------------------------------------------------

### Leucopenia

#### NSCLC

Four SRs summarized evidence of the add-on effect of Aidi injection, SFI, Kanglaite injection and various types of CHM for reducing chemotherapy induced leucopenia (CIL). Meta-analyses demonstrated positive effect of these CHM in reducing CIL, but results from Kanglaite injection appeared to be heterogeneous (I^2^ = 52%, p = 0.03). Subgroup analysis from Li 2013 showed that CHM were more effective when the baseline severity of CIL is higher (pooled RR = 0.36 in CIL grade III--IV versus pooled RR = 0.75 in CIL grade I--IV).

#### Colorectal cancer

Results from a SR showed that CHM tends to be more effective in treating more severe CIL, but this trend is not reflected in a subgroup analysis including only patients with grade IV CIL. Another SR showed that, when compared to FOLFOX4 (5-Fluorouracil + Leucovorin + Oxaliplatin) alone, the additional use of CHM provides significant improvement on patients with grade III--IV neutropenia.

#### Gastric cancer

One SR showed significant add-on benefits of CHM in reducing grade II--IV CIL (pooled OR = 0.26, 95% CI = 0.18--0.37).

#### Various types of cancer

A SR summarized evidence on astragalus injection plus chemotherapy versus chemotherapy alone in reducing grade I--IV CIL for various types of cancer patients. Meta-analysis showed a slight add-on benefit from astragalus injection (pooled RR = 0.84, 95% CI = 0.79--0.88). Another SR reported that, when compared to chemotherapy alone, the addition of CHM significantly improved grade I--IV CIL (pooled OR = 0.40, 95% CI = 0.23--0.68). However, both meta-analyses had significant heterogeneity.

### Nausea and vomiting

#### NSCLC

Evidence on CHM for reducing chemotherapy induced nausea and vomiting (CINV) were reviewed on Aidi injection, SFI, Kanglaite injection and various types of CHM. All meta-analyses showed favorable effect.

#### Liver cancer

Two SRs reviewed evidence of CHM for treating CINV. Both showed that CHM has a slightly positive effect in reducing CINV.

#### Colorectal cancer

Meta-analysis from a SR showed that when compared to chemotherapy alone, combination of CHM and chemotherapy significantly reduced grade III--IV CINV. Another SR reported that CHM tended to be more effective in managing more severe CINV, although no significant difference was seen in the outcomes of patients with grade I, II or IV CINV.

#### Gastric cancer

Evidence from one SR showed that the additional use of CHM provide a protective effect against grade II--IV CINV (pooled OR = 0.48, 95% CI = 0.34--0.66).

### Thrombocytopenia

#### NSCLC

Two SRs reported that SFI and various types of CHM can significantly improve thrombocytopenia in NSCLC patients.

#### colorectal cancer

A SR included one RCT (n = 42) found that, when compared to FOLFOX4 alone, additional use of CHM has no effect in reducing grade III--IV thrombocytopenia (RR = 1.00, 95% CI = 0.07--14.95).

#### Gastric cancer

Evidence from a SR showed favorable effects of CHM in reducing grade II--IV thrombocytopenia (pooled OR = 0.35, 95% CI = 0.14--0.86).

#### Various types of cancer

Evidence showed the adjuvant use of astragalus injection or CHM can significantly reduce thrombocytopenia in cancer patients. Significant heterogeneity was seen in the first meta-analysis.

### Anemia

#### NSCLC

Two SRs summarized evidence on SFI and CHM in preventing anemia. Results showed that the additional use of SFI significantly prevented the occurrence of grade III--IV anemia. However, this result is not consistent with results from another SR that summarized effects of a wide range of CHM. It is reported that CHM may significantly reduce grade I--IV anemia, but no significant difference was seen in the subgroup that only included grade III--IV patients.

#### Colorectal cancer

A SR showed that, when compared to FOLFOX4 alone, the additional use of CHM reduced the occurrence of grade III--IV anemia. However, no statistical difference was reached between the two groups.

#### Gastric cancer

Evidence from a SR showed that CHM plus chemotherapy can significantly reduce the occurrence of grade II--IV anemia, when compared to chemotherapy alone.

#### Various types of cancer

A SR suggested that the additional use of astragalus injection showed significant positive effect in reducing anemia grade I--IV in various types of cancer patients.

### Neurotoxicity

#### Colorectal cancer

Although evidence showed that the additional use of CHM may reduce neurotoxicity of chemotherapy, no significant difference was reached in either of the two identified SRs.

### Other chemotherapy related toxicity

#### Colorectal cancer

A SR summarized evidence on the combined use of CHM and FOLFOX4 for treating chemotherapy induced diarrhea and stomatitis in colorectal cancer patients. Although the additional use of CHM may reduce grade III--IV diarrhea and grade III--IV stomatitis, no statistical significant difference was reached in either meta-analysis.

#### Quality of evidence

More than half (65.9%) of evidence on CHM in reducing chemotherapy induced toxicity is of moderate quality, while 32.8% showed low quality and the remaining 2.3% is of very low quality.

### Adverse effect of CHM

Among the 51 included SRs, seven (13.7%) described adverse effect from CHM usage. Three reported that no AE were described among the included RCTs. Four SRs reported a wide range of adverse effect, including nausea, insomnia, stomatitis, hair loss, mild gastric bleeding, low-grade fever, dizziness, gastrointestinal discomfort, mild skin itch and rashes. All these symptoms disappeared after discontinuing the CHM treatment, or alleviated after symptomatic treatment.

Discussion
==========

This overview summarized evidence on the effect of CHM for cancer palliative care, on top of conventional treatment. We identified SRs on nine types of cancer, of which evidence on 13 specific CHM intervention were included. We also described results from SRs that did not set any restrictions on cancer diagnoses nor types of CHM interventions, which may increase the external validity of this overview as this indicates the real world practice of traditional Chinese medicine. In general, results from the identified SRs demonstrated add-on benefit of CHM in improving QoL among patients with various types of cancer, including NSCLC, liver cancer, gastric cancer, colorectal cancer, breast cancer and nasopharyngeal cancer.

For survival, it is observed that the additional use of CHM significantly improved 2-year, 3-year and 5-year survival rates in NSCLC patients, 2-year survival rate in lung cancer patients, 0.5-year, 1-year, 1.5-year, 2-year and 3-year survival rates in liver cancer patients, 2-year, 3-year, 5-year survival rates in gastric cancer patients, 0.5-year, 1-year, 2-year, 3-year, 4-year and 5-year survival rates in colorectal cancer patients, 3-year survival rate in nasopharyngeal cancer patients, 1-year survival rate in cervical cancer patients. In SRs synthesizing evidence on various types of cancer, improvement on 1-year and 2-year survival rate were also observed. However, conflicting results were observed for the 1-year survival rates of NSCLC and gastric cancer patients. Also, there seems to be no add-on effect from KS in improving 3-year survival rate of patients with esophageal cancer.

Evidence showed that the combination of CHM and chemotherapy significantly reduced leucopenia, nausea and vomiting, thrombocytopenia and anemia in NSCLC, gastric cancer patients. It also significantly reduced nausea and vomiting in liver cancer patients. In general, CHM appears to be useful in improving leucopenia, thrombocytopenia and anemia among various types of cancer. Nevertheless, available evidence cannot demonstrate clear add-on benefits of CHM in improving leucopenia, nausea and vomiting, thrombocytopenia, anemia, neurotoxicity, diarrhea and stomatitis in colorectal cancer patients.

Base on the evidence we identified, CHM may be considered as an adjuvant option to improve QoL among cancer patients. Evidence showed inconsistency in the effectiveness of CHM for improving survival rate and reducing chemotherapy and/or radiotherapy related toxicity in cancer patients. Although we attempted to include all key outcomes on cancer palliative care, only three outcomes were identified in this overview. For some common symptoms which conventional care has limited options, such as pain, fatigue, anorexia, insomnia, limbs edema and constipation[@b8][@b14], no relevant SR has been conducted. Finally, as the majority results were coming from Chinese population, the generalizability of the present results may be limited.

The methodological quality of included SRs was mediocre when compared to other SRs on CHM[@b15] or those focused on conventional medicine[@b16]. Good performance was noted on conducting comprehensive literature search, and on assessing and documenting risk of bias of included studies, with more than 80% SRs satisfying these two criteria. On the other hand, improvement should be made in the remaining nine AMSTAR items, especially in providing a protocol, reporting lists of both included and excluded studies, and disclosing conflict of interests for both the SR and included studies. That said, quality of evidence is not as poor as we expected. Majority of evidence on improving QoL, prolonging survival time and reducing chemotherapy inducted toxicity are judged to be of moderate quality in terms of effectiveness.

In addition, reporting quality of included SRs was unsatisfactory, often with little details on CHM and conventional treatments provided, as well as on how outcomes were measured. Future SR should comply with the PRISMA statement[@b17][@b18] such that it is more useable for policy makers and clinicians. Another limitation of the included SRs is that the majority of them did not mention results on CHM safety, only seven (13.7%) SRs reported adverse effects which were originated from CHM usage. Results from these seven SRs indicated that adverse events from CHM were mild, but a firm conclusion on the safety of CHM usage cannot be made as discovery of rare and longer term toxicities would require case-control and retrospective cohort designs. In the future, well reported observational studies and RCTs are needed to clarify the presence of short and long term toxicities of CHM.

Limitations on reporting were also noted among trials included in the SRs. Many trials were judged to have unclear risk of bias by the systematic reviewers, reflecting the lack of compliance to the CONSORT guideline for reporting[@b19][@b20][@b21][@b22]. It is unfortunate that poor reporting practice does not improve despite the availability of Chinese CONSORT[@b23]. This has limited us from excluding SRs that mainly report results from trials with high risk of bias, and the potential impact of this on the trustworthiness of the results should be highlighted. In addition, since the clinical evidence presented in all SRs were mainly obtained from trial reports published in mainland China, there was a potential risk of positive publication bias[@b22][@b24], although this phenomenon is not restricted to Chinese publications[@b25]. To prevent publication bias, it is recommended that all clinical trials protocols on the topic should register with a recognized platform (e.g. the Chinese Clinical Trial Registry)[@b26].

Although we did not set restriction on QoL measurement tool in our eligibility criteria, all included SRs reported such outcome using the KPS. KPS only measure general performance status, which might not be sufficient for assessing QoL of cancer patients comprehensively. Future trials are suggested to adopt more specific QoL measurement tool such as the Short Form 36 questionnaire, and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-core 30[@b27].

Major contributions of this overview are to comprehensively summarize; and to critically appraise all available evidence on CHM for cancer palliative care. Limitations on both reporting and methodological rigor of the existing SRs as well as primary studies were identified and suggestions were made on how these can be improved of future studies on this area. Clinical questions that are waiting for further researches were also identified through this study.

In conclusion, current clinical evidence indicated that CHM may be considered as a palliative care option for improving QoL among cancer patients. There are conflicting results on the effectiveness of CHM in prolonging survival and in reducing chemotherapy and/or radiotherapy related toxicities. Quality of evidence is moderate for these three outcomes. Also, future trials are suggested to investigate the effectiveness of CHM in managing common symptoms like pain, fatigue, anorexia, insomnia, limbs edema and constipation[@b8][@b14], in which conventional care options for these common cancer related symptoms were limited. Methodological quality of SRs in CHM for cancer palliative care is not satisfactory. To provide more rigorous evidence on the effectiveness of CHM, future SRs and trials must adhere to high methodological and reporting standards.

Methods
=======

Criteria for considering meta-analyses for inclusion
----------------------------------------------------

This overview only included SR with meta-analysis that quantitatively summarized evidence on CHM for cancer palliative care. SR is defined as an "attempt to identify, appraise and synthesize all the empirical evidence that meets pre-specified eligibility criteria to answer a given research question", in accordance to the Cochrane Handbook version 5.1.0.[@b28] Any SRs that meet the following criteria were included in this overview: i) Cochrane SR or non-Cochrane SR focusing on cancer palliative care with meta-analysis conducted; ii) meta-analyses must pooled clinical trials that evaluate the effectiveness of at least one CHM indexed in the 2010 China Pharmacopeia Chinese herbal medicine index[@b29]. The protocol of this overview has been registered in PROSPERO [(http://www.crd.york.ac.uk/PROSPERO/display_record.asp ?ID = CRD42015016171](http://(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID = CRD42015016171)).

Participants
------------

SR including clinical trials on patients diagnosed with any type of cancer and received at least one form of CHM for supportive or palliative care was considered eligible.

Interventions & control
-----------------------

CHM of any dosage form or route of administration was considered eligible in this overview. We included SRs that include studies providing any type of control treatment without CHM. These interventions include conventional treatment, placebo, chemotherapy, radiotherapy, or no treatment.

Outcomes of interest
--------------------

With an aim to provide a comprehensive picture of available clinical evidence on CHM for cancer palliative care, we included all cancer or treatment related outcomes measured using validated approaches. Special attention was paid to those symptoms that are frequently experienced by cancer patients but limited treatment choices are available from conventional medicine. These outcomes include cancer related pain, fatigue, anorexia, insomnia, limbs edema and constipation[@b8][@b14].

Literature search
-----------------

We conducted a comprehensive literature search in seven databases from their inception till July 2014. Both international databases (MEDLINE, EMBASE, Cochrane Database of Systematic Reviews (CDSR) and Database of Abstracts of Reviews of Effect (DARE)) and Chinese databases (Chinese Biomedical Databases (CBM), Wan Fang Digital Journals and Taiwan Periodical Literature Databases) were searched to identify potential SRs. Specialized search filter for reviews were used for MEDLINE and EMBASE[@b30]. Detailed search strategies are reported in [Appendix 1](#S1){ref-type="supplementary-material"}.

Literature selection, data extraction, methodological quality and quality of evidence assessment
------------------------------------------------------------------------------------------------

All retrieved citations were screened and assessed for their eligibility according to the inclusion criteria. For duplicate publications, the most updated version was selected.

The following data were extracted from each included SR: i) basic characteristics of the SR, including search date, number of included studies, total number of patients and bibliographic information; ii) detailed information on study design and patient, intervention, control and outcomes; and iii) statistical results, including pooled effects of each comparison for each outcome.

Methodological quality of included SRs was assessed with the Methodological Quality of Systematic Reviews (AMSTAR) Instrument[@b31], which was shown to be a reliable and valid tool for assessing the methodological quality of SRs[@b32][@b33]. Eleven aspects were assessed by using AMSTAR, with each aspect being judged as yes, no, can't answer or not applicable based on the information provided. Detailed operational guide for AMSTAR is provided in [Appendix 2](#S1){ref-type="supplementary-material"}.

Quality of evidence for each outcome was assessed using the Chinese and Integrative Medicine Evidence Rating System (CHIMERAS)[@b34]. Quality of evidence was judged across five levels (very low, low, moderate, high and very high) by considering rigors of both qualitative (direction of effect) and quantitative (effect size) conclusions.

Literature selection, data extraction, methodological quality and quality of evidence assessment were conducted by two researchers independently, with any disagreement resolved by discussion and consensus. Unresolved discrepancy was managed by a third reviewer.

Data synthesis
--------------

The effectiveness of CHM treatments was assessed at review level. We did not re-analyze the data of the primary trials included in the SR. We extracted the pooled effect estimation from each meta-analysis. Pooled relative risk (RR) or odds ratio (OR) for dichotomous outcomes, and mean difference (MD) for continuous outcomes accompanied with respective 95% confidence interval (CI) were reported.

Additional Information
======================

**How to cite this article**: Chung, V. C.H. *et al.* Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses. *Sci. Rep.* **5**, 18111; doi: 10.1038/srep18111 (2015).

Supplementary Material {#S1}
======================

###### Appendix 1-4

This study was funded by Chinese Medicine Department, Hong Kong Hospital Authority (Reference number: 8110016609.)

**Author Contributions** Study concept and design: V.C., E.H. and J.W. Acquisition of data: X.Y.W. and R.H. Interpretation of data: X.Y.W. and R.H. Figure 1 preparation: K.T. [Table 1](#t1){ref-type="table"} preparation: E.H. and E.Z. [Table 2](#t2){ref-type="table"} preparation: X.Y.W. and R.H. [Tables 3](#t3){ref-type="table"}--[5](#t5){ref-type="table"} preparation: S.W. and B.N. Drafting of the manuscript: X.Y.W. and V.C. Critical revision of the manuscript for important intellectual content: V.C., E.Z., B.N. and K.T. Administrative, technical, or material support: S.W. and J.W. All authors reviewed the manuscript, agreed to all the contents and agreed the submission.

![Flowchart of literature selection on meta-analyses of Chinese herbal medicines for cancer palliative care.\
Keys: CHM, Chinese herbal medicine; SR, systematic review.](srep18111-f1){#f1}

###### Characteristics of included meta-analyses on Chinese herbal medicine for cancer palliative care.

  First author and year of publication    Included study design   Search period       Cancer site (tumor stage)       No. of studies (No. of patients)        Nature of Chinese herbal medicine (CHM) interventions[\^](#t1-fn2){ref-type="fn"}                                 Nature of control interventions                                                                                           Outcomes reported
  -------------------------------------- ----------------------- --------------- ----------------------------------- ---------------------------------- ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  Ma, 2004                                  RCT or quasi-RCT          2003               NSCLC (TNM III--IV)                      10 (771)                                           CHM + chemotherapy (Cisplatin drugs)                                                     Cisplatin drugs chemotherapy alone                                                                                                 QOL
  Liu,2009                                         RCT              Sep. 2007                 CRC (NR)                            6 (334)                                                 Jianpi CHM + chemotherapy                                                                   Chemotherapy alone                                                              Chemotherapy related toxicity, including: leucopenia, nausea and vomiting, neurotoxicity
  Wu, 2009a                                        RCT              Jul. 2008            NSCLC (TNM III--IV)                     19 (1380)                                             Aidi injection + NP chemotherapy                                                              NP chemotherapy alone                                                                         chemotherapy related toxicity: leucopenia, nausea and vomiting
  Wu, 2009b                                        RCT              Feb. 2009        Liver cancer (TNM III--IV)                  45 (3236)                                                        CHM + TACE                                                                              TACE alone                                                                                                        Survival rate
  Zhu,2009                                  RCT or quasi-RCT        Aug. 2008            NSCLC (TNM III--IV)                     16 (1041)                                            KLT+ NP or MVP or GP chemotherapy                                                       NP or MVP or GP chemotherapy alone                                                                                                 QOL
  Chen, 2010                                       RCT              Oct. 2009                NSCLC (NR)                           11 (796)                                               CHM+ MVP or NP chemotherapy                                                             MVP or NP chemotherapy alone                                                                                               Survival rate
  Dong, 2010a                               RCT or quasi-RCT           NR                   Various (NR)                         12 (1230)                                           Astragalus injection + chemotherapy                                                              Chemotherapy alone                                                                      QOL, chemotherapy related toxicity: leucopenia, anemia, thrombocytopenia
  Fu, 2010                                         RCT              Oct. 2009               Various (NR)                         24 (4150)                                                    CHM + chemotherapy                                                         Chemotherapy alone or Chemotherapy + placebo                                                                Chemotherapy related toxicity: leucopenia, thrombocytopenia
  Guo, 2010                                        RCT                2009                Liver cancer (NR)                      33 (2619)                                                        CHM + TACE                                                                     TACE alone or TACE + placebo                                                                                                    QOL
  Zhou, 2010                                       RCT                 NR                Gastric cancer (NR)                      13 (877)                                                    CHM + chemotherapy                                                                      Chemotherapy alone                                                                                                    Survival rate
  Dong, 2010b                                      RCT              Apr. 2010            NSCLC (TNM III--IV)                     29 (2062)                                          SFI + platinum containing chemotherapy                                                  Platinum containing chemotherapy alone                                                QOL, chemotherapy related toxicity: leucopenia, anemia, thrombocytopenia, and nausea and vomiting
  Cui, 2011                                        RCT              Dec. 2010            NSCLC (TNM III--IV)                      9 (584)                                                    KS + NP chemotherapy                                                                    NP chemotherapy alone                                                                                                       QOL
  Ma, 2011a                                        RCT              Jun. 2010            NSCLC (TNM III--IV)                      11 (752)                                                   KS + NP chemotherapy                                                                    NP chemotherapy alone                                                                                                       QOL
  Ma, 2011b                                        RCT              Jun. 2010             Liver cancer (NR)                       11 (NR)                                                         KS + TACE                                                                               TACE alone                                                                                                     QOL, survival rate
  Wang, 2011                                       RCT              Aug. 2010            Gastric cancer (NR)                      4 (304)                                                     KLT + chemotherapy                                                                      Chemotherapy alone                                                                                                    Survival rate
  Qiao, 2011                                       RCT              Mar. 2010     Nasopharyngeal cancer (TNM I--IV)               9 (795)                                  Yiqi Yangyin and Qingre Huoxue decoction + radiotherapy                                                    Radiotherapy alone                                                                                                 QOL, survival rate
  Zhuang, 2011                              RCT or qusai-RCT        Nov. 2010            NSCLC (TNM III--IV)                      6 (416)                                                   Kang Ai injection + TP                                                                   TP chemotherapy alone                                                                                                       QOL
  Guo, 2012                                 RCT or quasi-RCT        Aug. 2011               CRC (TNM IV)                         20 (1304)                                            CHM + chemotherapy or radiotherapy                                                      Chemotherapy or radiotherapy alone                                                                                         Survival rate, QOL
  Jin, 2012                                        RCT              Oct. 2011               Various (NR)                          5 (373)                               Extract of *Ganoderma lucidum* (chemotherapy or radiotherapy)                   Chemotherapy + placebo or chemotherapy alone or radiotherapy+ conventional care                                                                          QOL
  Yang, 2012                                RCT or quasi-RCT          2006                Lung cancer (NR)                        10 (853)                                       CHM\* + chemotherapy or radiotherapy or both                                                Chemotherapy or radiotherapy or both.                                                                                          Survival rate
  Qin, 2012                                        RCT              Oct. 2011            NSCLC (TNM III--IV)                      13 (972)               Kang Ai injection + paclitaxel or gemcitabine or navelbin + platinum containing chemotherapy   Paclitaxel or gemcitabine or navelbin + platinum containing chemotherapy alone                                                                           QOL
  Cai, 2012                                        RCT                2011           Gastric cancer (TNM I--IV)                    9 (NR)                                                     SFI + chemotherapy                                                                      Chemotherapy alone                                                                                                         QOL
  Wang, 2012a                               RCT or qusai-RCT          2010                    CRC (NR)                            9 (518)                                                     CHM + chemotherapy                                                                      Chemotherapy alone                                                                                                         QOL
  Li, 2012a                                 RCT or quasi-RCT          2011                    CRC (NR)                           14 (1081)                                                    CHM+ chemotherapy                                                                       Chemotherapy alone                                                                                                    Survival rate
  Li, 2012b                                        RCT              Aug. 2011             Liver cancer (NR)                      47 (3854)                                                        CHM + TACE                                                                              TACE alone                                                                              Survival rate, chemotherapy related toxicity: nausea and vomiting
  Liu, 2012                                        RCT                2011               Breast cancer (NR)                        6 (NR)                                                     KS + chemotherapy                                                                       Chemotherapy alone                                                                                                         QOL
  Fan, 2012                                        RCT              Jun. 2011         Breast cancer (TNM I--IV)                   6 (496)                                                     KS + chemotherapy                                                                       Chemotherapy alone                                                                                                         QOL
  Ma, 2012                                         RCT              Jun. 2010            NSCLC (TNM III--IV)                      8 (696)                                                    KS +TP chemotherapy                                                                     TP chemotherapy alone                                                                                                       QOL
  Shi, 2012                                 RCT or quasi-RCT          2010               Gastric cancer (NR)                     21 (1178)                                                    CHM + chemotherapy                                                                      Chemotherapy alone                                                                 Survival rate, Chemotherapy related toxicity: leucopenia, anemia, thrombocytopenia.
  Wang, 2012b                                      RCT              Jun. 2012       Gastric cancer (TNM III--IV)                 44 (3088)                                                 CHM + conventional care                                                                  Conventional care alone                                                                                                      QOL
  Rong, 2012                                       RCT              Nov. 2011            NSCLC (TNM III--IV)                     18 (1108)                                                    CHM + Chemotherapy                                                                      Chemotherapy alone                                                                                                    Survival rate
  Wang, 2012c                               RCT or qusai-RCT        Sep. 2011               Various (NR)                          11 (618)                                           Xiaoaiping injection + chemotherapy                                                              Chemotherapy alone                                                                                                         QOL
  Zhang, 2012                                      RCT              Dec. 2011           Various (TNM II--IV)                     16 (1539)                                            SFI + chemotherapy or radiotherapy                                                      Chemotherapy or radiotherapy alone                                                                                                 QOL
  Xu, 2012                                  RCT or qusai-RCT           NR           Cervical cancer (TNM II--IV)                 18 (1657)                               CHM + radiotherapy or CHM + radiotherapy + conventional care                               Radiotherapy alone or radiotherapy + conventional care                                                                                  Survival rate
  Cheung, 2013                                     RCT              Oct. 2012         Liver cancer (TNM II--IV)                  67 (5211)                                                        CHM + TACE                                                                              TACE alone                                                                           QOL, survival rate, Chemotherapy related toxicity: nausea and vomiting
  Li, 2013                                         RCT              Sep. 2012            NSCLC (TNM III--IV)                      24 (NR)                                                     CHM + chemotherapy                                                                      Chemotherapy alone                                                  QOL, survival rate, Chemotherapy related toxicity: nausea and vomiting, leucopenia, anemia and thrombocytopenia.
  Xie, 2013                                 RCT or quasi-RCT        Jan. 2013       Gastric cancer (TNM III--IV)                 15 (1008)                                                 Huachansu + chemotherapy                                                                   Chemotherapy alone                                                                                                    Survival rate
  Du, 2013                                         RCT                2012             Esophageal cancer (NR)                      5 (NR)                                             KS + chemotherapy or radiotherapy                                              chemo or radiotherapy or (chemo + radiotherapy) alone                                                                                  Survival rate
  Tian, 2013                                       RCT              Nov. 2012                NSCLC (NR)                          24 (1845)                                            CHM + chemotherapy or radiotherapy                                               chemotherapy alone or chemotherapy + radiotherapy                                                                                    Survival rate
  Jiang, 2013                                      RCT                2013                Liver cancer (NR)                      16 (1105)                                                        CHM + TACE                                                                              TACE alone                                                                                                        Survival rate
  Liu, 2013                                 RCT or quasi-RCT          2012                   NSCLC (NR)                           6 (346)                                           Zilongjin (bailongpian) + chemotherapy                                                  chemotherapy (GP, NP or MVP, MVP) alone                                                                                              QOL
  Xu, 2013                                         RCT              Oct. 2012            Gastric cancer (NR)                      15 (NR)                                                     CHM + Chemotherapy                                                                      Chemotherapy alone                                                                                                    Survival rate
  Xiao, 2013                                       RCT                2012                   NSCLC (NR)                           10 (588)                                 Xiaoaiping injection + platinum containing chemotherapy                                          Platinum containing chemotherapy alone                                                                                               QOL
  Su, 2013                                  RCT or quasi-RCT        Oct. 2012               Various (NR)                          82 (NR)                                             KS + chemotherapy or radiotherapy                                                       Chemotherapy or radiotherapy alone                                                                                            Survival rate
  Yan, 2013                                        RCT              Feb. 2012            NSCLC (TNM III--IV)                      10 (687)                                                   KLT+NP chemotherapy                                                                     NP chemotherapy alone                                                                                                       QOL
  Sheng, 2013                                      RCT                2011                   NSCLC (NR)                           38 (NR)                                         SFI + chemotherapy (GP or NP or TP or DP)                                                Chemotherapy (GP or NP or TP or DP) alone                                                                                             QOL
  He, 2013                                         RCT              Sep. 2012            NSCLC (TNM III--IV)                     19 (1110)                                   Shenfu injection + platinum containing chemotherapy                                            Platinum containing chemotherapy alone                                                                                               QOL
  Chen, 2014                                       RCT              Dec. 2012               CRC (TNM IV)                          13 (940)                                                      CHM + FOLFOX 4                                                                           FOLFOX4 alone                                    Survival rate, Chemotherapy related toxicity: neutropenia, nausea and vomiting, neurotoxicity, diarrhea, anemia, thrombocytopenia, and stomatitis
  Xu, 2014                                         RCT              Dec. 2012            NSCLC (TNM III--IV)                     17 (1605)                                                    KLT + chemotherapy                                                                      Chemotherapy alone                                                                           Chemotherapy related toxicity: nausea and vomiting, leucopenia
  Liu, 2014                                        RCT              Jun. 2012               CRC (TNM IV)                          13 (781)                                                    CHM + chemotherapy                                                                      Chemotherapy alone                                                                                                    Survival rate
  Wang, 2014                                       RCT                2012          Gastric cancer (TNM III--IV)                 10 (1020)                                                       SFI+FOLFOX4                                                                             FOLFOX4 alone                                                                                                           QOL

^\*^Included all types of CHM.

^\^^CHM denotes the inclusion of all types of Chinese herbal medicines. The use of generic terms "chemotherapy" or "radiotherapy" denotes that the specific treatments used were not described in the original meta-analyses publications.

Keys: CHM, Chinese herbal medicine; CRC, colorectal cancer; DP, Docetaxel + Cisplatin; FOLFOX, the FOLFOX regimen refers to 5-Fluorouracil + Leucovorin combined with Oxaliplatin; GP, Gemcitabine + Cisplatin; KLT, Kanglaite injection; KS, Compound Kushen injection; MVP, Mitomycin + Vindesine + Cisplatin; NP, Cisplatin + Vinorelbine; NR, not reported; NSCLC, non-small lung cell cancer; QOL, quality of life; RCT, randomized controlled trial; SFI, Shenqi Fuzheng injection; SR, systematic review; TACE, Transcatheter arterial chemoembolization; TNM, tumor-node-metastasis stage; TP, Paclitaxel + Cisplatin.

###### Methodological quality of included meta-analyses on Chinese herbal medicine for cancer palliative care.

  First author and year of publication    AMSTAR item                                                                                                            
  -------------------------------------- ------------- ----------- ----------- ----------- --------- ----------- ----------- ----------- ----------- ----------- ---------
  Ma, 2004                                     N           NR           Y          NR          N          N           N           N           Y           N          N
  Liu, 2009                                    N            Y           Y           N          N          N           N           Y           Y           N          N
  Wu, 2009a                                    N           NR          NR          NR          N          N           Y           Y          NR           Y          N
  Wu, 2009b                                    N            Y           Y           Y          N          N          NR           Y          NR           Y          N
  Zhu, 2009                                    N           NR           Y           Y          N          N           Y           Y           Y           Y          N
  Chen, 2010                                   N           NR           N          NR          N          N           N           N           N           Y          N
  Dong, 2010                                   N            Y           Y           Y          N          N           Y           Y           N           Y          N
  Fu, 2010                                     N            Y           Y           N          N          N           Y           N           Y           Y          N
  Guo, 2010                                    N           NR           Y          NR          N          N           Y           Y           N           Y          N
  Zhou, 2010                                   N           NR           Y           N          N          N           Y           N           Y           N          N
  Dong, 2010                                   N            Y           Y           N          N          N           Y           Y           Y           Y          N
  Cui, 2011                                    N            Y           Y           Y          N          N           Y           Y           Y           Y          N
  Ma, 2011a                                    N           NR           Y          NR          N          N           Y           Y           Y           Y          N
  Ma, 2011b                                    N           NR           Y          NR          N          N           Y           Y           Y           Y          N
  Wang, 2011                                   N            Y           Y          NR          N          Y           Y           N           Y           N          N
  Qiao, 2011                                   N            Y           Y           Y          N          N           Y           Y           Y           Y          N
  Zhuang, 2011                                 N            Y           Y          NR          N          N           Y           Y           Y           Y          N
  Qin, 2012a                                   Y            Y           Y           Y          Y          Y           Y           N           Y           N          N
  Jin, 2012                                    Y            Y           Y           Y          Y          N           Y           Y           Y           N          N
  Yang, 2012                                   N           NR           Y           N          N          N           Y           N           Y           N          N
  Qin, 2012b                                   N           NR           Y           N          N          N           Y           N           Y           Y          N
  Cai, 2012                                    N            Y           Y           Y          N          Y           Y           Y           Y           N          N
  Wang, 2012a                                  N           NR           Y           N          N          N           Y           N           Y           Y          N
  Li, 2012a                                    N            Y           Y           N          N          Y           Y           Y           Y           Y          N
  Li, 2012b                                    N            Y           Y           Y          N          Y           Y           Y           Y           N          N
  Liu, 2012                                    N           NR           Y           N          N          N           Y           Y           Y           Y          N
  Fan, 2012                                    N           NR           Y           Y          N          Y           Y           N           Y           N          N
  Ma, 2012                                     N           NR           Y          NR          N          N           Y           Y           Y           Y          N
  Shi, 2012                                    N            Y           Y           N          N          N           Y           Y           N           N          N
  Wang, 2012b                                  N            Y           Y           N          N          N          NR           N           Y           Y          N
  Rong, 2012                                   N            Y           Y           N          N          N           Y           N           Y           Y          N
  Wang, 2012c                                  N           NR           Y           N          N          N           Y           N           Y           Y          N
  Zhang, 2012                                  N            Y           Y           N          N          Y           Y           Y           Y           Y          N
  Xu, 2012                                     N            Y           Y           Y          N          N           Y           Y           Y           N          N
  Cheung, 2013                                 N            Y           Y           Y          N          Y           Y           Y           N           Y          N
  Li, 2013                                     N            Y           Y          NR          N          Y           Y           Y           Y           N          N
  Xie, 2013                                    N            Y           Y           Y          N          Y          NR           N          NR           Y          N
  Du, 2013                                     N            Y           Y          NR          N          N           Y           Y           N           Y          N
  Tian, 2013                                   N            Y           Y           Y          N          N           Y           Y           Y           Y          N
  Jiang, 2013                                  N           NR           Y           N          N          N           Y           N           Y           Y          N
  Liu, 2013                                    N            Y           Y           Y          N          N           Y           Y           N           N          N
  Xu, 2013                                     N           NR           Y           N          N          N           Y           N           Y           N          N
  Xiao, 2013                                   N            Y           Y           Y          N          Y           Y           Y           Y           N          N
  Su, 2013                                     N            Y           Y          NR          N          Y           Y           Y           Y           Y          N
  Yan, 2013                                    N           NR           Y          NR          N          N           Y           N           Y           Y          N
  Sheng, 2013                                  N            Y           Y           Y          N          N           Y           Y           Y           Y          N
  He, 2013                                     N            Y           Y           Y          N          Y           Y           Y           Y           N          N
  Chen, 2014                                   N            Y           Y           Y          N          Y           Y           Y          NR           Y          N
  Xu, 2014                                     N            Y           Y           N          N          Y           Y           N           N           Y          N
  Liu, 2014                                    N           NR           Y          NR          N          N          NR           N           Y           N          N
  Wang, 2014                                   N            Y           Y           N          N          Y           Y           Y           Y           Y          N
  \# of Yes (%)                             2 (3.9)     32 (62.7)   49 (96.1)   19 (37.3)   2 (3.9)   16 (31.4)   44 (86.3)   31 (60.8)   39 (76.5)   33 (64.7)   0 (0.0)

Keys: CHM, Chinese herbal medicine; N, no; NR, not reported; Y, yes (meta-analysis fulfilling the criteria); \# of Yes, number of yes; AMSTAR item: 1. Was an 'a priori' design provided? 2. Was there duplicate study selection and data extraction? 3. Was a comprehensive literature search performed? 4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 5. Was a list of studies (included and excluded) provided? 6. Were the characteristics of the included studies provided? 7. Was the scientific quality of the included studies assessed and documented? 8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 9. Were the methods used to combine the findings of studies appropriate? 10. Was the likelihood of publication bias assessed? 11. Was the conflict of interest included?

###### Chinese Herbal Medicine for Improving QOL among Cancer Patients: Overview of Meta-Analyses Results.

  First author and year of publication                              Comparison[\^](#t3-fn4){ref-type="fn"}                                       Outcome assessment method             No. of studies (No. of patients)    Pooled results (95% CI)        Heterogeneity I^2^ (%)        Quality of evidence
  -------------------------------------- --------------------------------------------------------------------------------------------- ---------------------------------------------- ---------------------------------- --------------------------- --------------------------------- ---------------------
  Cui, 2011                                                                      KS+NP vs. NP                                           Improvement rate[\*](#t3-fn1){ref-type="fn"}                5(NR)                  OR: 2.38 \[1.43, 3.95\]                  0.0                      Moderate
  Ma, 2011a                                                                      KS+NP vs. NP                                                         Improvement rate                              7(537)                 OR: 2.78 \[1.87, 4.15\]                  0.0                      Moderate
  Ma, 2012b                                                                      KS+TP vs. TP                                                         Improvement rate                              6(475)                 OR: 3.26 \[2.22, 4.80\]                  0.0                      Moderate
  Zhu, 2009                                                                      KLT+NP vs. NP                                          Responder rate [\#](#t1-fn2){ref-type="fn"}                 4(234)                 RR: 1.34 \[1.14, 1.58\]                  0.0                      Moderate
  Yan, 2013                                                                      KLT+NP vs. NP                                                        Improvement rate                              7(505)                 RR: 1.73 \[1.34, 2.23\]    57.0[¶](#t3-fn3){ref-type="fn"}        Moderate
  Dong, 2010b                                     SFI + platinum containing chemotherapy vs. platinum containing chemotherapy                          Responder rate                              20(1336)                RR: 1.57 \[1.45, 1.70\]                 24.8                      Moderate
  Sheng, 2013                                                         SFI + chemotherapy vs. chemotherapy                                              Responder rate                              27(1805)                RR: 1.40 \[1.30, 1.52\]                 44.0                      Moderate
  Zhuang, 2011                                                           Kang Ai injection +TP vs. TP                                                 Improvement rate                              5(356)                 OR: 3.13 \[1.88, 5.20\]                  0.0                      Moderate
  Qin, 2012b                                                   Kang Ai injection+ chemotherapy vs. chemotherapy                                       Improvement rate                             11(804)                 OR: 1.87 \[1.60, 2.19\]                  0.0                      Moderate
  Ma, 2004                                                            CHM + chemotherapy vs. chemotherapy                                              Responder rate                               7(555)                 OR: 3.36 \[2.47, 4.57\]                  NR                       Moderate
  Li, 2013                                                            CHM+ chemotherapy vs. chemotherapy                                              Improvement rate                              6(526)                 RR: 3.25 \[2.22, 4.77\]                 51.0                      Moderate
  Liu, 2013                                                       Zijinglong + chemotherapy vs. chemotherapy                                          Improvement rate                              6(346)                 RR: 4.14 \[2.80, 6.12\]    77.0[¶](#t3-fn3){ref-type="fn"}        Moderate
                                                                           Zijinglong + MVP vs. MVP                                                   Improvement rate                              3(150)                RR: 12.72\[4.70, 34.43\]                 42.0                      Moderate
  Xiao, 2013                              Xiaoaiping injection+platinum containing chemotherapy vs. platinum containing chemotherapy                  Improvement rate                             10(588)                 OR: 1.57 \[1.12, 2.20\]                  0.0                      Moderate
  He, 2013                                                      Shenfu Injection +chemotherapy vs. chemotherapy                                       Improvement rate                              3(198)                 OR: 2.72 \[1.48, 5.00\]                  0.0                      Moderate
  *Liver cancer*                                                                                                                                                                                                                                                                       
  Ma, 2011b                                                                    KS+TACE vs. TACE                                                       Improvement rate                              6(447)                 OR: 2.58 \[1.71, 3.89\]                  0.0                      Moderate
  Guo,2010                                                                     CHM+TACE vs. TACE                                                      Improvement rate                             26(1882)                OR: 1.78 \[1.58, 2.01\]                  0.0                      Moderate
  Cheung, 2013                                                                 CHM+TACE vs. TACE                                                      Improvement rate                             27(2014)                RR: 1.74 \[1.57, 1.93\]                  0.0                      Moderate
                                                                                                                                                         KPS score                                  9(477)                MD: 10.03 \[8.98, 11.07\]   95.0[¶](#t3-fn3){ref-type="fn"}        Moderate
  *Gastric cancer*                                                                                                                                                                                                                                                                     
  Cai, 2012                                                           SFI+ chemotherapy vs. chemotherapy                                              Improvement rate                              8(534)                 RR: 3.14 \[2.11, 4.69\]                  7.0                      Moderate
  Wang, 2014                                                                SFI+FLOFOX4 vs. FLOFOX4                                                    Responder rate                               6(505)                 OR: 1.48 \[1.26, 1.57\]                 33.0                      Moderate
  Wang, 2012b                                                    CHM+ conventional care vs. conventional care                                            KPS score                                 17(1359)                MD: 0.51 \[0.21, 1.82\]    86.0[¶](#t3-fn3){ref-type="fn"}           Low
  *Colorectal cancer*                                                                                                                                                                                                                                                                  
  Guo, 2012                                                           CHM + chemotherapy vs. chemotherapy                                             Improvement rate                              8(605)                 RR: 1.85 \[1.55, 2.21\]                  NR                       Moderate
  Wang, 2012a                                                         CHM+ chemotherapy vs. chemotherapy                                              Improvement rate                              6(282)                 OR: 3.48 \[2.17, 5.58\]                  0.0                      Moderate
  *Breast cancer*                                                                                                                                                                                                                                                                      
  Liu, 2012                                                            KS+ chemotherapy vs. chemotherapy                                              Improvement rate                              4(370)                 OR: 2.98 \[1.85,4.80\]                   0.0                      Moderate
  Fan, 2012                                                            KS+ chemotherapy vs. chemotherapy                                              Improvement rate                             4 (316)                 RR: 3.44 \[2.09, 5.67\]                  0.0                      Moderate
  *Nasopharyngeal cancer*                                                                                                                                                                                                                                                              
  Qiao, 2011                                                          CHM + radiotherapy vs. radiotherapy                                              Responder rate                               2(166)                 RR: 1.60 \[1.30, 1.96\]                  0.0                      Moderate
  *Various types of cancer*                                                                                                                                                                                                                                                            
  Dong, 2010a                                                 Astragalus extract + chemotherapy vs. chemotherapy                                       Responder rate                               6(641)                 RR: 1.46 \[1.29, 1.66\]                 39.1                      Moderate
  Jin, 2012                               *Ganoderma lucidum* extract + chemotherapy or radiotherapy vs. chemotherapy or radiotherapy                 Improvement rate                              3(284)                 RR: 2.51 \[1.86, 3.40\]                 48.0.                       High
  Wang, 2012c                                                 Xiaoaiping injection+ chemotherapy vs. chemotherapy                                     Improvement rate                              9(568)                 RR: 1.80 \[1.49, 2.18\]                 27.0                      Moderate
  Zhang, 2012                                         SFI+ chemotherapy or radiotherapy vs. chemotherapy or radiotherapy                              Improvement rate                              7(623)                 OR: 3.07 \[2.15, 4.39\]                  0.0                      Moderate

^\*^QOL measured with the Karnofsky Performance Status (KPS) scale. A KPS score increment \>10 is defined as an improvement. Improvement rate  =  number of patients who had a KPS increment \>10 / total number of patients, this definition apply to all improvement rate in Table 3.

^\#^A KPS score increment \>0 is defined as an improvement. Responder rate  =  number of patients who had a KPS increment \>0 / total number of patients, this definition apply to all improvement rate in Table 3.

^¶^p \< 0.05 for the heterogeneity test;

^\^^CHM denotes the inclusion of all types of Chinese herbal medicines. The use of generic terms "chemotherapy" or "radiotherapy" denote that the specific treatments used were not described in the original meta-analyses publications.

Keys: CHM, Chinese herbal medicine; CI confidence interval; FOLFOX, the FOLFOX regimen refers to 5-Fluorouracil + Leucovorin combined with Oxaliplatin; KLT, Kanglaite injection; KS, Compound Kushen injection; MD, mean difference; MVP, Mitomycin + Vindesine + Cisplatin; NP, Cisplatin + Vinorelbine; NR, not reported; OR, odds ratio; QOL, quality of life; RR, relative risk; SFI, Shenqi Fuzheng injection; TACE, Transcatheter arterial chemoembolization; TP, Paclitaxel + Cisplatin.

###### Chinese Herbal Medicine for Improving Survival Rate among Cancer Patients: Overview of Meta-Analyses Results.

  First author and year of publication                                         Comparison[\^](#t4-fn2){ref-type="fn"}                                         Duration of follow up (year)   No. of studies (No. of patients)   Pooled results (95% CI)          Heterogeneity I2 (%)         Quality of evidence
  -------------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------ ---------------------------------- -------------------------- ---------------------------------- ---------------------
  *Non-small cell lung cancer*                                                                                                                                                                                                                                                               
  Chen, 2010                                                                     CHM+ chemotherapy vs. chemotherapy                                                        1                              4(338)                OR: 1.29 \[0.83, 2.01\]                  0.0                          Low
  CHM+ chemotherapy vs. chemotherapy                                                              2                                                                      2(180)                  OR: 2.26 \[1.16, 3.99\]                  58\.                           Low                            
  Rong, 2012                                                                     CHM+ chemotherapy vs. chemotherapy                                                        1                              5(NR)                  RR: 1.35\[1.09, 1.66\]                  0.0                       Moderate
  Li, 2013                                                                       CHM+ chemotherapy vs. chemotherapy                                                        1                              7(608)                 RR: 1.36\[1.15, 1.60\]                  0.0                       Moderate
  Tian, 2013                                                                     CHM+ chemotherapy vs. chemotherapy                                                        1                              5(NR)                  OR: 1.56\[1.08, 2.25\]                  0.0                       Moderate
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        3                              5(NR)                  OR: 2.59\[1.51, 4.45\]                  0.0                         High
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        5                              5(NR)                  OR: 2.45\[1.24, 4.84\]                  0.0                         High
  *Lung cancer (Type unspecified)*                                                                                                                                                                                                                                                           
  Yang, 2012                                                                     CHM+ chemotherapy vs. chemotherapy                                                        2                              4(406)                 OR: 3.44\[2.04, 5.80\]                  0.0                       Moderate
  *Liver cancer*                                                                                                                                                                                                                                                                             
  Wu, 2009b                                                                               CHM+TACE vs. TACE                                                               0.5                             15(NR)                 RR: 1.10\[1.04, 1.15\]                  0.0                       Moderate
                                                                                          CHM+TACE vs. TACE                                                                1                              22(NR)                 RR: 1.26\[1.17, 1.36\]                  7.0                       Moderate
                                                                                          CHM+TACE vs. TACE                                                               1.5                             4(NR)                  RR: 1.71\[1.02, 2.91\]    70.0[\*](#t4-fn1){ref-type="fn"}           Low
                                                                                          CHM+TACE vs. TACE                                                                2                              15(NR)                 RR: 1.72\[1.40, 2.03\]                  0.0                       Moderate
                                                                                          CHM+TACE vs. TACE                                                                3                              8(NR)                  RR: 2.40\[1.65, 3.49\]                  0.0                         High
  Ma, 2011b                                                                               KS+TACE VS. TACE                                                                 1                              4(283)                OR: 2.18 \[1.29, 3.69\]                  0.0                         High
  Li, 2012b                                                              CHM+TACE vs. TACE alone or TACE+ conventional care                                                1                             17(1238)                RR: 1.36\[1.25, 1.49\]                  15.0                      Moderate
  *Liver cancer*                                                                                                                                                                                                                                                                             
  Cheung, 2013                                                                            CHM+TACE vs. TACE                                                               0.5                            22(2278)               RR: 1.12 \[1.07, 1.16\]                  0.0                       Moderate
                                                                                          CHM+TACE vs. TACE                                                                1                             30(2963)               RR: 1.40 \[1.32, 1.50\]                  0.0                       Moderate
                                                                                          CHM+TACE vs. TACE                                                               1.5                             5(327)                RR: 1.89 \[1.44, 2.49\]    63.0[\*](#t4-fn1){ref-type="fn"}        Moderate
                                                                                          CHM+TACE vs. TACE                                                                2                             19(2220)               RR: 1.75 \[1.55, 1.99\]                  30.0                      Moderate
                                                                                          CHM+TACE vs. TACE                                                                3                             11(1338)               RR: 2.51 \[1.97, 3.19\]                 67.0\*                       High
  Jiang, 2013                                                                             CHM+TACE vs. TACE                                                                1                             12(991)                 OR: 2.15\[1.63, 2.85\]                  21.0                        High
  *Gastric cancer*                                                                                                                                                                                                                                                                           
  Zhou,2010                                                                      CHM+ chemotherapy vs. chemotherapy                                                        3                              4(409)                OR: 2.33 \[1.53, 3.56\]                  22.4                      Moderate
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        5                              5(655)                OR: 1.84 \[1.31, 2.59\]                  0.0                       Moderate
  Wang, 2011                                                                     KLT + chemotherapy vs. chemotherapy                                                       1                              2(94)                 OR: 6.74 \[2.74, 16.62\]                 0.0                         High
  Shi, 2012                                                                      CHM+ chemotherapy vs. chemotherapy                                                        1                              3(289)                 OR: 1.10\[1.01, 1.21\]                  0.0                          Low
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        2                              3(289)                 OR: 1.29\[1.11, 1.50\]                  0.0                       Moderate
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        3                              3(311)                 OR: 1.43\[1.15, 1.75\]                  0.0                       Moderate
  Xie, 2013                                                                   Huachansu + chemotherapy vs. chemotherapy                                                    1                              4(NR)                  RR: 1.25\[0.73, 2.14\]                  0.0                       Moderate
  Xu, 2013                                                                       CHM+ chemotherapy vs. chemotherapy                                                        1                              4(399)                 OR: 2.17\[1.15, 4.08\]                  0.0                       Moderate
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        3                              4(407)                 OR: 2.26\[1.51, 3.39\]                  0.0                       Moderate
  *Colorectal cancer*                                                                                                                                                                                                                                                                        
  Guo, 2012                                                                      CHM + chemotherapy vs. chemotherapy                                                       1                             4 (238)                 RR: 1.39\[1.15, 1.69\]                   NR                       Moderate
                                                                                 CHM + chemotherapy vs. chemotherapy                                                       3                              2(129)                RR: 2.23 \[1.05, 4.73\]                   NR                       Moderate
  Li, 2012a                                                                      CHM+ chemotherapy vs. chemotherapy                                                       0.5                             3(134)                 OR: 2.19\[1.10, 4.34\]                  0.0                         High
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        1                             12(930)                 OR: 2.83\[2.01, 3.99\]                  0.0                         High
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        2                              6(454)                 OR: 2.59\[1.59, 4.24\]                  0.0                         High
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        3                              8(657)                 OR: 2.25\[1.54, 3.30\]                  0.0                         High
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        4                              1(122)                 OR: 2.29\[1.08, 4.82\]                   NA                         High
                                                                                 CHM+ chemotherapy vs. chemotherapy                                                        5                              4(394)                 OR: 2.32\[1.55, 3.48\]                  0.0                         High
  Chen, 2014                                                                           CHM+FOLFOX4 vs. FOLFOX4                                                             1                              3(279)                 RR: 1.51\[1.19, 1.90\]                  0.0                       Moderate
  Liu, 2014                                                                      CHM+ chemotherapy vs. chemotherapy                                                        1                              4(339)                 OR: 2.60\[1.46, 4.63\]                  29.0                      Moderate
  *Nasopharyngeal cancer*                                                                                                                                                                                                                                                                    
  Qiao, 2011                                                                     CHM + radiotherapy vs. radiotherapy                                                       3                              3(307)                RR: 1.30 \[1.03, 1.63\]                  46.0                      Moderate
  *Esophageal cancer*                                                                                                                                                                                                                                                                        
  Du, 2013                                KS + radiotherapy alone or KS + chemotherapy + radiotherapy vs. radiotherapy alone or chemotherapy + radiotherapy                3                              2(142)                 OR: 1.86\[0.96, 3.62\]                  21.4                         Low
  *Cervical cancer*                                                                                                                                                                                                                                                                          
  Xu, 2012                                                    CHM+ chemotherapy or radiotherapy vs. chemotherapy or radiotherapy alone                                     1                              4(427)                 OR: 4.16\[1.97, 8.78\]                   NR                       Moderate
  *Various types of cancer*                                                                                                                                                                                                                                                                  
  Su, 2013                                                     KS+ chemotherapy or radiotherapy vs. chemotherapy or radiotherapy alone                                     1                              9(656)                 RR: 1.41\[1.23, 1.63\]                  0.0                       Moderate
                                                               KS+ chemotherapy or radiotherapy vs. chemotherapy or radiotherapy alone                                     2                              6(408)                 RR: 1.76\[1.23, 2.48\]                  32.7                      Moderate

^\*^p \< 0.05 for the heterogeneity test;

^\^^CHM denotes the inclusion of all types of Chinese herbal medicines. The use of generic terms "chemotherapy" or "radiotherapy" denote that the specific treatments used were not described in the original meta-analyses publications.

^¶^Effects on dichotomous data were summarized with risk ratio (RR) or odds ratio (OR) to measure the risk of experiencing certain outcome in the treatment group as compared to the control group.

Keys: CHM, Chinese herbal medicine; CI confidence interval; FOLFOX, the FOLFOX regimen refers to 5-Fluorouracil + Leucovorin combined with Oxaliplatin; KLT, Kanglaite injection; KS, Compound Kushen injection; NR, not reported; OR, odds ratio; RR, relative risk; TACE, Transcatheter arterial chemoembolization.

###### Chinese Herbal Medicine for Reducing Chemotherapy Related Toxicity: Overview of Meta-Analyses Results.

  First author and year of publication      Cancer cite                       Comparison[\^](#t5-fn4){ref-type="fn"}                     Outcome assessment method[\#](#t5-fn2){ref-type="fn"}   No. of studies (No. of patients)   Pooled results (95%CI)[¶](#t5-fn5){ref-type="fn"}        Heterogeneity I^2^ (%)        Quality of evidence
  --------------------------------------- ---------------- ---------------------------------------------------------------------------- ------------------------------------------------------- ---------------------------------- --------------------------------------------------- ---------------------------------- ---------------------
  *Leucopenia*                                                                                                                                                                                                                                                                                                            
  Wu,2009a                                     NSCLC                                Aidi injection + NP vs. NP                                               Grade II--IV                                   13 (1000)                            RR: 0.59\[0.52, 0.67\]                                NR                          Low
  Dong,2010b                                   NSCLC        SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy                       Grade III--IV                                   20(1643)                            RR: 0.37\[0.29, 0.47\]                               0.0                       Moderate
  Li, 2013                                     NSCLC                            CHM+ chemotherapy vs. chemotherapy                                           Grade III--IV                                    9(666)                             RR: 0.36\[0.26, 0.52\]                               0.0                       Moderate
                                                                                CHM+ chemotherapy vs. chemotherapy                                            Grade I--IV                                     8(603)                             RR: 0.75\[0.67, 0.84\]                              20.0,                      Moderate
  Xu, 2014                                     NSCLC                            KLT+ chemotherapy vs. chemotherapy                                           Grade III--IV                                   10(982)                             OR: 0.54\[0.38, 0.77\]                 52.0[\*](#t5-fn3){ref-type="fn"}        Moderate
  Liu,2009                                      CRC                             CHM+ chemotherapy vs. chemotherapy                                              Grade I                                       6(334)                             RR: 0.50\[0.31, 0.80\]                               7.0                       Moderate
                                                                                CHM+ chemotherapy vs. chemotherapy                                             Grade II                                       6(334)                             RR: 0.37\[0.21, 0.66\]                               0.0                          Low
                                                                                CHM+ chemotherapy vs. chemotherapy                                             Grade III                                      5(281)                             RR: 0.47\[0.19, 1.19\]                               0.0                          Low
                                                                                CHM+ chemotherapy vs. chemotherapy                                             Grade IV                                       2(129)                             RR: 0.13\[0.02, 1.05\]                               0.0                          Low
  Chen, 2014                                    CRC                                  CHM+FOLFOX4 vs. FOLFOX4                                           Neutropenia grade III--IV                             10(692)                             RR: 0.33\[0.18, 0.60\]                               0.0                          Low
  Shi, 2012                                Gastric cancer                       CHM+ chemotherapy vs. chemotherapy                                           Grade II--IV                                     7(353)                             OR: 0.26\[0.18, 0.37\]                               35.0                      Moderate
  Dong, 2010a                                 Various                  Astragalus injection + chemotherapy vs. chemotherapy                                   Grade I--IV                                     9(927)                             RR: 0.84 \[0.79, 0.88\]                77.3[\*](#t5-fn3){ref-type="fn"}           Low
  Fu, 2010                                    Various                           CHM+ chemotherapy vs. chemotherapy                                            Grade I--IV                                    11(2169)                            OR: 0.40 \[0.23, 0.68\]                55.0[\*](#t5-fn3){ref-type="fn"}        Moderate
  *Nausea and vomiting*                                                                                                                                                                                                                                                                                                   
  Wu, 2009a                                    NSCLC                                Aidi injection + NP vs. NP                                               Grade II--IV                                    10 (781)                            RR: 0.52\[0.43, 0.62\]                                NR                          Low
  Dong, 2010b                                  NSCLC        SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy                       Grade III--IV                                   14(1031)                            RR: 0.32\[0.22, 0.47\]                               0.0                       Moderate
  Li, 2013                                     NSCLC                            CHM+ chemotherapy vs. chemotherapy                                           Grade III--IV                                    4(295)                             RR: 0.24\[0.12, 0.50\]                               0.0                       Moderate
  Xu, 2014                                     NSCLC                            KLT+ chemotherapy vs. chemotherapy                                           Grade III--IV                                   10(982)                             OR: 0.54\[0.38, 0.77\]                 52.0[\*](#t5-fn3){ref-type="fn"}        Moderate
  Li, 2012b                                 Liver cancer                CHM+TACE vs. TACE alone or TACE+ conventional care                                    Grade I--IV                                    11(816)                             RR: 0.79\[0.69, 0.91\]                 48.0[\*](#t5-fn3){ref-type="fn"}        Moderate
  Cheung, 2013                              Liver cancer                                CHM+TACE vs. TACE                                                     Grade I--IV                                     9(581)                             RR: 0.86 \[0.76, 0.96\]                              40.0                      Moderate
  Liu, 2009                                     CRC                             CHM+ chemotherapy vs. chemotherapy                                              Grade I                                       6(334)                             RR: 0.85 \[0.60, 1.20\]                              0.0                       Moderate
                                                                                CHM+ chemotherapy vs. chemotherapy                                             Grade II                                       6(334)                             RR: 0.51 \[0.31, 0.84\]                              0.0                       Moderate
                                                                                CHM+ chemotherapy vs. chemotherapy                                             Grade III                                      6(334)                             RR: 0.49 \[0.23, 1.05\]                              0.0                       Moderate
                                                                                CHM+ chemotherapy vs. chemotherapy                                             Grade IV                                       1(61)                              RR: 0.11 \[0.01, 1.92\]                               NA                       Very low
  Chen, 2014                                    CRC                                  CHM+FOLFOX4 vs. FOLFOX4                                                 Grade III--IV                                    9(633)                             RR: 0.34\[0.18, 0.66\]                               0.0                       Moderate
  Shi, 2012                                Gastric cancer                       CHM+ chemotherapy vs. chemotherapy                                           Grade II--IV                                     5(279)                             OR: 0.48\[0.34, 0.66\]                               0.0                       Moderate
  *Thrombocytopenia*                                                                                                                                                                                                                                                                                                      
  Dong, 2010b                                  NSCLC        SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy                       Grade III--IV                                   18(1335)                            RR: 0.33\[0.21, 0.52\]                               0.0                       Moderate
  Li, 2013                                     NSCLC                            CHM+ chemotherapy vs. chemotherapy                                           Grade III--IV                                    6(557)                             RR: 0.34\[0.17, 0.68\]                               0.0                       Moderate
                                                                                CHM+ chemotherapy vs. chemotherapy                                            Grade I--IV                                     6(494)                             RR: 0.43\[0.31, 0.60\]                               0.0                       Moderate
  Chen, 2014                                    CRC                                  CHM+FOLFOX4 vs. FOLFOX4                                                 Grade III--IV                                    1(42)                              RR: 1.00\[0.07, 14.95\]                               NA                       Moderate
  Shi, 2012                                Gastric cancer                       CHM+ chemotherapy vs. chemotherapy                                           Grade II--IV                                     4(225)                             OR: 0.35\[0.14, 0.86\]                               0.0                       Moderate
  Dong, 2010a                                 Various                       Astragalus + chemotherapy vs. chemotherapy                                        Grade I--IV                                     8(829)                             RR: 0.69 \[0.56, 0.85\]                83.5[\*](#t5-fn3){ref-type="fn"}        Moderate
  Fu, 2010                                    Various                           CHM+ chemotherapy vs. chemotherapy                                            Grade I--IV                                    7(1162)                             OR: 0.41 \[0.27, 0.62\]                              8.9                       Moderate
  *Anemia*                                                                                                                                                                                                                                                                                                                
  Dong, 2010b                                  NSCLC        SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy                       Grade III--IV                                   15(1161)                            RR: 0.44\[0.30, 0.66\]                               0.0                       Moderate
  Li, 2013                                     NSCLC                            CHM+ chemotherapy vs. chemotherapy                                            Grade I--IV                                     6(553)                             RR: 0.64\[0.51, 0.80\]                               25.0                      Moderate
                                                                                CHM+ chemotherapy vs. chemotherapy                                           Grade III--IV                                    6(536)                             RR: 0.58\[0.26, 1.29\]                               0.0                       Moderate
  Chen, 2014                                    CRC                                  CHM+FOLFOX4 vs. FOLFOX4                                                 Grade III--IV                                    3(220)                             RR: 0.30\[0.05, 1.89\]                               0.0                          Low
  Shi, 2012                                Gastric cancer                       CHM+ chemotherapy vs. chemotherapy                                           Grade II--IV                                     4(207)                             OR: 0.38\[0.25, 0.58\]                               43.0                      Moderate
  Dong, 2010a                                 Various                       Astragalus+ chemotherapy vs. chemotherapy                                         Grade I--IV                                     4(371)                             RR: 0.42 \[0.27, 0.65\]                              33.1                      Moderate
  *Neurotoxicity*                                                                                                                                                                                                                                                                                                         
  Liu,2009                                      CRC                             CHM+ chemotherapy vs. chemotherapy                                              Grade I                                       5(273)                             RR: 0.84 \[0.57, 1.24\]                              0.0                          Low
                                                                                CHM+ chemotherapy vs. chemotherapy                                             Grade II                                       5(273)                             RR: 0.73 \[0.45, 1.19\]                              0.0                          Low
                                                                                CHM+ chemotherapy vs. chemotherapy                                             Grade III                                      5(273)                             RR: 0.40 \[0.13, 1.25\]                              0.0                          Low
  Chen, 2014                                    CRC                                  CHM+FOLFOX4 vs. FOLFOX4                                                 Grade III--IV                                    7(529)                             RR: 0.39\[0.15, 1.00\]                               0.0                          Low
  *Other chemotherapy related toxicity*                                                                                                                                                                                                                                                                                   
  Chen, 2014                                    CRC                                  CHM+FOLFOX4 vs. FOLFOX4                                            Diarrhea grade III--IV                                5(448)                             RR: 0.39\[0.11, 1.42\]                               0.0                          Low
                                                                                     CHM+FOLFOX4 vs. FOLFOX4                                           Stomatitis grade III--IV                               2(210)                             RR: 0.43\[0.08, 2.31\]                               0.0                          Low

Keys: CHM, Chinese herbal medicine; CI confidence interval; CRC, colorectal cancer; FOLFOX, the FOLFOX regimen refers to 5--Fluorouracil + Leucovorin combined with Oxaliplatin; KLT, Kanglaite injection; NA, not applicable; NSCLC, non-small lung cell cancer; NP, Cisplatin + Vinorelbine; NR, not reported; OR, odds ratio; RR, relative risk; SFI, Shenqi Fuzheng injection; TACE, Transcatheter arterial chemoembolization.

^\#^All chemotherapy toxicities were measured with the World Health Organization toxicity criteria;

^\*^p \< 0.05 for the heterogeneity test;

^\^^CHM denotes the inclusion of all types of Chinese herbal medicines. The use of generic terms "chemotherapy" or "radiotherapy" denote that the specific treatments used were not described in the original meta-analyses publications.

^¶^Effects on dichotomous data were summarized with risk ratio (RR) or odds ratio (OR) to measure the risk of experiencing certain outcome in the treatment group as compared to the control group.
